cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
2018/09/26 by Daniel J. Brat, Kenneth Aldape, Howard Colman +10 · 32 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Glioma Diagnosis and Treatment #Radiomics and Machine Learning in Medical Imaging #Cancer Genomics and Diagnostics
paper · doi:10.1007/s00401-018-1913-0
Citations
Cited by
- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
- cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
- Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
- Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
- Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know
- Newly Diagnosed Glioblastoma: A Review on Clinical Management. [europepmc]
- Molecular pathology of tumors of the central nervous system. [europepmc]
- Genetic and molecular epidemiology of adult diffuse glioma. [europepmc]
- Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype. [europepmc]
- Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. [europepmc]
- IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. [europepmc]
- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. [europepmc]
- Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. [europepmc]
- The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. [europepmc]
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. [europepmc]
- Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. [europepmc]
- Proteogenomic and metabolomic characterization of human glioblastoma. [europepmc]
- A Review of Newly Diagnosed Glioblastoma. [europepmc]
- TERT Promoter Alterations in Glioblastoma: A Systematic Review. [europepmc]
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. [europepmc]
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. [europepmc]
- Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. [europepmc]
- Prognostic and Predictive Biomarkers in Gliomas. [europepmc]
- Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. [europepmc]
- Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. [europepmc]
- The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression. [europepmc]
- Major Features of the 2021 WHO Classification of CNS Tumors. [europepmc]
- The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. [europepmc]
- The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview. [europepmc]
- The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. [europepmc]